Prometheus Biosciences Inc

Prometheus Biosciences — Technical Presentation (December 2022)

32 slides from Prometheus Biosciences's technical presentation, Dec 7, 2022

  1. Slide 1: ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Data Readouts

    Exhibit 99.1 ARTEMIS-UC Phase 2 APOLLO-CD Phase 2a DATA READOUTS December 7, 2022

  2. Slide 2: Disclaimer: Forward Looking Statements & Market Data

    Disclaimer: Forward Looking Statements & Market Data We caution you that this presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial posit

  3. Slide 3: Agenda

    Agenda Introduction & Executive Summary Mark McKenna, Chairman & CEO ARTEMIS-UC & APOLLO-CD Allison Luo, MD, Chief Medical Officer Phase 2 Study Results Translational Data Olivier Laurent, PhD, Chief Scientific Officer Closing Remarks Mark McKenna, Chairman & CEO Analyst Q&A Prometheus Team & KOL: B

  4. Slide 4: Introductory Remarks

    Introductory Remarks Mark McKenna, Chairman & CEO 4

  5. Slide 5: ARTEMIS-UC Phase 2 Topline Results

    ARTEMIS-UC Phase 2 Topline Results Allison Luo, MD, Chief Medical Officer 5

  6. Slide 6: Executive Summary: Positive Results from Phase 2 ARTEMIS-UC Study

    Executive Summary: Positive Results from Phase 2 ARTEMIS-UC Study Study population: refractory • 47% were previously treated with at least 1 advanced therapy* with high disease severity: • 73% with baseline Mayo endoscopy subscore of 3 Primary and all ranked secondary endpoints for Cohort 1 were met

  7. Slide 7: ARTEMIS-UC Placebo-Controlled Phase 2 Study Design

    ARTEMIS-UC Placebo-Controlled Phase 2 Study Design COHORT 1 TO EVALUATE EFFICACY OF PRA023 Key Inclusion Criteria Induction Primary • Moderately to severely active UC Endpoint • No/insufficient response and/or intolerance to conventional or advanced therapy Randomization PRA023 (N=60) Open Label Ext

  8. Slide 8: Subject Disposition in the 12-Week Double-Blind Induction Period

    Subject Disposition in the 12-Week Double-Blind Induction Period Randomized N=135 Randomized and Treated (ITT) N=135 Placebo, N=67 PRA023, N=68 Discontinued treatment, N=7 (10.4%) Discontinued treatment, N=0 Primary reason: Primary reason: Adverse events, n=2 (3.0%) Adverse events, n=0 Lack of effic

  9. Slide 9: Baseline Disease Characteristics and Demographics

    Baseline Disease Characteristics and Demographics Placebo (N = 67) PRA023 (N = 68) Overall (N = 135) Age, years, mean (SD) 42.2 (16.3) 40.4 (14.4) 41.3 (15.3) Female, n (%) 29 (43%) 34 (50%) 63 (47%) Weight, kg, mean (SD) 77 (18.5) 74 (19.6) 75 (19) Geographic region, n (%) Eastern Europe 39 (58%) 3

  10. Slide 10: Significant Differences in Primary and Secondary Endpoints at Week 12 vs Placebo

    Subjects Treated with PRA023 Achieved Significant Differences in Primary and Secondary Endpoints at Week 12 Compared to Placebo 100% Placebo N=67 PRA023 N=68 D 43.8% 90% p <0.0001 80% D 30.8% 66.2% 70% p <0.0001 D 25.0% 60% p <0.0001 50% 36.8% 40% 26.5% 30% 22.4% 20% 6.0% 10% 1.5% 0% Clinical Remiss

  11. Slide 11: Treatment with PRA023 Led to Symptom Control as Early as Week 1

    Treatment with PRA023 Led to Symptom Control as Early as Week 1 7 Placebo PRA023 6 *** 5 4 *** *** *** 3 6 0 1 10 12 Week 11 Nominal p-values, * p<0.05, ** p<0.01, ***p<0.001. Error bars depict Standard Error Partial Mayo Score (mean +/- SE)

  12. Slide 12: Analysis of ARTEMIS-UC Cohort for CDx Effect

    Analysis of ARTEMIS-UC Cohort 1 for CDx Effect Reinforces Confidence in Precision Approach 60 • First prospective use of a companion diagnostic in IBD • Payer/physician research suggests 10% absolute increase is a compelling improvement over all-comers 40 37.5% • Based on efficacy data and confidenc

  13. Slide 13: PRA023 Was Well-Tolerated As Induction Therapy

    PRA023 Was Well-Tolerated As Induction Therapy Placebo PRA023 Treatment Emergent Adverse Events, n (%) N = 67 N = 68 Subjects with any AE (n, %) 27 (40.3%) 28 (41.2%) Subjects with any Severe (Grade ≥ 3) AE 3 (4.5%) 0 † Subjects with any Drug-Related AE 1 (1.5%) 3 (4.4%) Subjects with an AE Leading

  14. Slide 14: Most Common Treatment-Emergent Adverse Events Comparable Across Groups

    Most Common (>2 Subjects in Any Group) Treatment-Emergent Adverse Events Are Comparable Across Treatment Groups Placebo PRA023 Adverse Events, n (%) N = 67 N = 68 COVID-19 3 (4.5%) 5 (7.4%) Upper respiratory tract infection 3 (4.5%) 1 (1.5%) Headache 3 (4.5%) 3 (4.4%) Colitis ulcerative 6 (9.0%) 1 (

  15. Slide 15: ARTEMIS-UC: Highly Differentiated Profile of Strong Efficacy with Favorable Tolerability

    ARTEMIS-UC: Highly Differentiated Profile of Strong Efficacy with Favorable Tolerability Strong Efficacy Results No Safety Signal Identified PRA023 was well-tolerated with no safety 12-Week Clinical Remission delta 25% signal identified 12-Week Endoscopic Improvement delta 30.8% Low Immunogenicity F

  16. Slide 16: APOLLO-CD Phase 2a Results

    APOLLO-CD Phase 2a Results Allison Luo, MD, Chief Medical Officer 16

  17. Slide 17: Executive Summary: Positive Results from Phase 2a APOLLO-CD Study

    Executive Summary: Positive Results from Phase 2a APOLLO-CD Study Study population was highly refractory with 70.9% biologic-experienced Successful Proof of Concept for PRA023 for the induction of endoscopic response and clinical remission in CD Endoscopic Response vs. 12% historical placebo p = 0.0

  18. Slide 18: APOLLO-CD Study Design

    APOLLO-CD Study Design Phase 2a, Multi-Center, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of PRA023 in Subjects with Moderately to Severely Active Crohn’s Disease Open-Label Extension RESPONDERS (decrease in CDAI of ≥100 points or CDAI < 150) Induction (N = 55) PRA023 25

  19. Slide 19: High Retention of Subjects in the 12-Week Induction Period

    High Retention of Subjects in the 12-Week Induction Period Treated, N = 55 Discontinued treatment, N = 2 (3.6%) Primary reason: Adverse events, n = 1 (1.8%) Lack of efficacy, n = 1 (1.8%) Completed Induction, N = 53 (96.4%) 19

  20. Slide 20: Baseline Characteristics and Demographics

    Baseline Characteristics and Demographics PRA023 (N = 55) Age, years, mean (SD) 39.1 (15.7) Female, n (%) 21 (38.2%) Weight, kg, mean (SD) 77.6 (20.6) Geographic region, n (%) 33 (60%) North America 13 (23.6%) Eastern Europe 7 (12.7%) Western Europe 2 (3.6%) Rest of world (Australia) Duration of dis

  21. Slide 21: Significant Differences for Primary and Secondary Endpoints vs Historic Placebo

    PRA023 Achieved Significant Differences for Primary and Secondary Endpoints at Week 12 Compared to Historic Placebo 70.0% p < 0.001 60.0% 50.0% p = 0.002 40.0% 30.0% 49.1% 20.0% 10.0% 26.0% 0.0% Endoscopic Response Clinical Remission P-values were computed for the testing of the null hypothesis of 1

  22. Slide 22: PRA023 Reduced Symptoms and Signs of Disease as Measured by Mean CDAI

    PRA023 Reduced Symptoms and Signs of Disease as Measured by Mean CDAI – Statistically Significant Improvement as Early as Week 1 300 ** *** 250 *** *** 200 *** 150 0 1 6 10 2 12 Weeks Nominal p-values, * p<0.05, ** p<0.01, ***p<0.001. Error bars depict Standard Error. 22 CDAI, Mean (+/-SE)

  23. Slide 23: PRA023 Was Well-Tolerated As Induction Therapy

    PRA023 Was Well-Tolerated As Induction Therapy All-causality TEAEs Treatment-related TEAEs (N = 55) (N = 55) Subjects with ≥ 1 AE(s) 43 (78.2%) 4 (7.3%) 8 (14.5%) 0 (0%) Subjects with ≥ 1 Serious AEs (SAEs) 3 (5.5%) 0 (0%) Subjects with ≥ 1 Severe (Grade ≥ 3) AE(s) 2 (3.6%) 0 (0%) Subjects discontin

  24. Slide 24: Most Common Treatment-Emergent Adverse Events During Induction

    Most Common (>2 Subjects) Treatment-Emergent Adverse Events During Induction Are As Expected for CD Study PRA023 Adverse Events, n (%) N = 55 6 (10.9%) COVID-19 Urinary Tract Infection 5 (9.1%) 5 (9.1%) Crohn’s disease 4 (7.3%) Anemia 3 (5.5%) Nasopharyngitis 3 (5.5%) Fatigue 24

  25. Slide 25: Analysis of APOLLO-CD Confirms Relevance of SNPs Used on Diagnostic Assay

    Analysis of APOLLO-CD Confirms Relevance of SNPs Used on Diagnostic Assay • Predictive power of the predefined SNPs was validated using an alternative Crohn’s disease-specific algorithm 60 • Patient selection using the alternate algorithm resulted in 45.0% 45.0% endoscopic response versus 26% in all

  26. Slide 26: APOLLO-CD: Strong Proof of Concept with Favorable Tolerability

    APOLLO-CD: Strong Proof of Concept with Favorable Tolerability Established POC No Safety Signal Identified PRA023 was well-tolerated with no safety 12-Week Endoscopic Response 26.0% signal identified 12-Week Clinical Remission 49.1% Low Immunogenicity Signal in CDx+ Low ADA level of 14.5% in Crohn’s

  27. Slide 27: Fibrosis & Inflammation Biomarkers

    Fibrosis & Inflammation Biomarkers Olivier Laurent, PhD, Chief Scientific Officer 27

  28. Slide 28: PRA023 Impact on Markers of Inflammation and Fibrosis in APOLLO-CD

    PRA023 Had a Statistically Significant Impact on Multiple Markers of Inflammation and Fibrosis in APOLLO-CD PRA023 reduced biomarkers of active fibrosis in disease tissue • Reduced expression of fibrosis gene signatures and individual genes involved in fibrotic tissue remodeling • Decreased proporti

  29. Slide 29: PRA023 Reduced Fibrosis Pathways in Disease Tissue

    PRA023 Reduced Fibrosis Pathways in Disease Tissue PRA023 reduced: • Expression of a composite signature of 24-genes associated with penetrating 1 fibrosis • Level of expression in individual genes (MMP3, MMP9, COL1A1) • Proportion of activated fibroblasts in disease tissue After Before After Before

  30. Slide 30: PRA023 Reduced Inflammatory Pathways in Disease Tissue

    PRA023 Reduced Inflammatory Pathways in Disease Tissue PRA023 reduced: • Pro-inflammatory cytokines in the circulation (IL-1β, IL-6, IL-17A, IL-22 and IL-9) while increasing IL-10 • Expression of Th1 and Th17 in disease tissue • CD4+ effector T cells in disease tissue Before After Before After treat

  31. Slide 31: Two Positive Studies Position PRA023 for Potential Leadership in IBD and Beyond

    Two Positive Studies Position PRA023 for Potential Leadership in IBD and Beyond TWO POSITIVE TRIALS PIONEERING PRECISION First precision medicine results in IBD Positive studies in both UC and CD provide confidence to bring disease- with highly competitive efficacy and specific CDx into Ph 3 for UC

  32. Slide 32: Question & Answer

    Bruce Sands, MD Question & Answer Chief of Gastroenterology Mt. Sinai Health System Prometheus Team with KOL 32

Prometheus Biosciences — Technical Presentation (December 2022) on 6ix